Sunday, July 3, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Exploring happy hypoxia in COVID-19 patients

by Medical Finance
in Coronavirus
Study: Silent hypoxia is not an identifiable characteristic in patients with COVID-19 infection. Image Credit: bangoland/Shutterstock
9
SHARES
101
VIEWS
Share on FacebookShare on Twitter

In a recent study published in Respiratory Medicine, researchers reported that silent hypoxia was not unique to coronavirus disease 2019 (COVID-19).

Study: Silent hypoxia is not an identifiable characteristic in patients with COVID-19 infection. Image Credit: bangoland/Shutterstock
Study: Silent hypoxia is not an identifiable characteristic in patients with COVID-19 infection. Image Credit: bangoland/Shutterstock

Background

Silent hypoxemia syndrome, well-tolerated hypoxemia with relatively less dyspnea, and its colloquial term ‘happy hypoxia’ were introduced in journalistic and clinical settings to describe the physiologic response of patients to pneumonitis caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Hypoxemia relative to the fraction of inspired oxygen (FiO2) is believed to be a better marker for COVID-19 severity than absolute hypoxemia.

The peripheral oxygen saturation (SpO2)-to-FiO2 ratio (SFR) is used analogously with arterial oxygen tension (PaO2)-to-FiO2 ratio (PFR), which describes the severity of acute respiratory distress syndrome (ARDS). The respiratory rate oxygenation (ROX) index quantified as the SFR-to-respiratory rate ratio might predict the need to intubate COVID-19 patients. The association between higher respiratory rate and failure of non-invasive oxygenation is contradictory to the notion that asymptomatic hypoxemia might be associated with poorer outcomes.

About the study

In the present retrospective study, researchers assessed whether happy hypoxia in COVID-19 patients was an identifiable characteristic in COVID-19 ARDS and associated with the need for intensive care.

The authors performed an observational cohort study of adults admitted to Nottingham University Hospitals with a suspected or confirmed diagnosis of COVID-19. Patient-related data were obtained from electronic records from February 21, 2020, to August 31, 2021. Suspected patients were included in the COVID-19-positive cohort if found positive for SARS-CoV-2 within 10 days.

Nursing observations were collected when a patient was suspected of or confirmed with COVID-19 for 14 days until ICU admission, discharge, or in-hospital death. Patient outcomes (ICU admission and all-cause mortality within 60 days) and primary diagnosis codes were extracted. FiO2, SFR, and ROX scores were computed when not explicitly documented. Whether happiness, i.e., impaired physiologic response to hypoxemia, was associated with poorer outcomes was evaluated by modeling the physiologic response to (absolute or relative) hypoxemia in the COVID-19 cohort alone.

Findings

From the 14,214 complete observations among 1,586 patients, more than 75% were positive for COVID-19 within 10 days of onset of symptoms. COVID-19 patients had a significantly higher temperature, respiratory rate, and lower heart rate than non-COVID-19 patients. Moreover, the COVID-19 cohort had a lower ROX index (3.1/min), implying a higher respiratory rate for a given degree of relative hypoxemia.

An increase of 0.3 breath per minute (Bpm) in respiratory rate among all patients was observed with every 1% decrease in SpO2. Similarly, a 0.1 Bpm decrease was noted for every 10 unit decrease in SFR among all patients. Overall, COVID-19 patients with severe absolute hypoxemia had a 1 Bpm higher respiratory rate, 7 bpm lower heart rate, and 0.3 °C higher temperature than non-COVID-19 patients.

For those in the COVID-19 cohort with severe relative hypoxemia, the respiratory rate was higher by 2 Bpm, 10 bpm lower heart rate, and 0.2 °C higher temperature than non-COVID-19 patients. The ROX index was 2.088/min lower in COVID-19 patients when adjusted for ethnicity and age, indicating a higher respiratory rate across any given degree of relative hypoxemia.

Among the COVID-19 patients, 67% of patients were not escalated to intensive care despite hypoxemia. Of these, 396 survived ICU stay, and 122 died within 60 days of symptom development.  Across the COVID-19 patients with severe relative hypoxemia, ICU-admitted patients had a 4 Bpm higher respiratory rate and 8 bpm higher heart rate than ward patients. The respiratory rate was higher for deceased patients by 5 Bpm and heart rate by 10 bpm.

Similarly, for COVID-19 patients with absolute hypoxemia, those under intensive care had a 7 bpm higher heart rate and 4 Bpm higher respiratory rate than survivors. Those who did not survive had a 5 Bpm higher respiratory rate and 8 bpm higher heart rate than survivors on ward-based care alone. After adjusting for ethnicity and age, the ROX index was significantly lower in ICU-admitted and deceased patients than survivors.

Conclusions

The study results showed that COVID-19 patients have a markedly distinct physiologic response to hypoxemia (higher respiratory rate) to any level of hypoxemia than non-COVID-19 subjects. While asymptomatic hypoxemia might be a phenomenon in any patient with respiratory failure, it (happiness) is not observed more frequently in COVID-19 patients than in non-COVID-19 patients.

The data presented here refuted that COVID-19 patients were more ‘happy’ with hypoxemia than non-COVID-19 subjects. The authors acknowledge that there were no compelling reasons to support a therapeutic approach for COVID-19 patients with respiratory failure other than currently available, proven standard ARDS care, nor do the findings support that physiologic happiness was associated with poorer outcomes.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Lung abnormalities may remain detectable long after COVID-19 pneumonia

As US nears 1 million covid deaths, one hard-hit county grapples with unthinkable loss

by Medical Finance
July 3, 2022
0

Connie Houtz didn't think covid would be that bad. She'd seen many people in this rural hamlet in central Pennsylvania...

Study: Bats host the most virulent—but not the most dangerous—zoonotic viruses. Image Credit: shutter_o / Shutterstock.com

Bats carry some of the most virulent, but not the most dangerous zoonotic viruses

by Medical Finance
July 3, 2022
0

The current coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered a...

Study: Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. Image Credit: angellodeco / Shutterstock.com

TLR7 and MARK1 genomic variants impact COVID-19 prognosis

by Medical Finance
July 3, 2022
0

As of April 3, 2022, coronavirus disease 2019 (COVID-19) has caused almost 6.2 million deaths worldwide. While in many developed...

Study: Case of a pregnant woman with probable prolonged SARS-CoV-2 viral shedding 221 days after diagnosis. Image Credit: Myriam B / Shutterstock.com

The longest duration of SARS-CoV-2 positivity after initial diagnosis

by Medical Finance
July 3, 2022
0

A new Journal of Infection and Chemotherapy study describes an immunocompetent individual with prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shedding...

Study: Screening of wild deer populations for exposure to SARS-CoV-2 in the United Kingdom, 2020-2021. Image Credit: Mark Cane / Shutterstock

No evidence of SARS-CoV-2 in the U.K.’s wild deer population

by Medical Finance
July 3, 2022
0

A new study accepted for publication in the journal Transboundary and Emerging Diseases assesses the potential exposure of U.K. deer to the severe acute...

COVID-19 incinerators set new record for merseyside manufacturer

COVID-19 incinerators set new record for merseyside manufacturer

by Medical Finance
July 3, 2022
0

A global waste management specialist has completed its first ever air-freighted incinerator system in record time, to help United Arab...

Next Post
Surveying communities may be a useful tool for predicting COVID-19 case trajectories

5 things you should know about ‘free’ at-home covid tests

Small cluster of neurons in the brain stem found to coordinate vocalization with breathing

Buffy Wicks turns her health history into legislation

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine - a prospective observational study. Image Credit: Chaay_Tee / Shutterstock.com
    BNT162b2 booster vaccination induces robust humoral and cellular immune responses
  • Study: Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice. Image Credit: PhotobyTawat/Shutterstock
    Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply